Gilead CMO nets 270 shares from RSU vesting

Gilead’s Chief Medical Officer saw RSUs vest into common stock, with part of the shares withheld to cover exercise price or taxes.

Rhea-AI Filing Summary

Gilead Sciences, Inc. (GILD) reported that Chief Medical Officer Dietmar Berger had restricted stock units vest into 533 shares of common stock on September 10, 2026. Of these, 263 shares were delivered or withheld to cover the exercise price or tax liability, leaving 270 net shares acquired as common stock. The RSU award follows a four-year vesting schedule, and no Rule 10b5-1 trading plan is reported for these transactions.

Insider Trade Summary

533 shares exercised/converted

Exercise 3 txns

Insider Berger Dietmar

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit F1, F2	533	--	--
Exercise	Common Stock F1	533	--	--
Exercise Price or Tax Liability	Common Stock	263	$144.81	$38K

Holdings After Transaction: Restricted Stock Unit — 46,395 contracts (Direct); Common Stock — 19,522 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
2. F2. The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

Key Figures

RSUs exercised: 533 shares Common shares acquired: 533 shares Shares delivered/withheld for exercise price or tax liability: 263 shares +4 more

7 metrics

RSUs exercised 533 shares Restricted stock units converting into common stock on September 10, 2026

Common shares acquired 533 shares Shares received upon RSU conversion on September 10, 2026

Shares delivered/withheld for exercise price or tax liability 263 shares Code F disposition on September 10, 2026

Implied value per withheld share $144.81 per share Value used for 263-share payment of exercise price or tax liability

RSUs held after transaction 46,395 units Restricted stock units directly held following the RSU-related transaction

Initial vesting portion 25.0% Portion of RSUs vesting on the first anniversary of the grant date

Ongoing quarterly vesting rate 6.25% per quarter Remaining RSUs vest quarterly after the first anniversary until fully vested

Key Terms

Restricted Stock Unit, vesting schedule, exercise or conversion of derivative security, exercise price or tax liability

4 terms

Restricted Stock Unit financial

"Each restricted stock unit represents the contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

vesting schedule financial

"The restricted stock units have a 4-year vesting schedule."

A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.

exercise or conversion of derivative security financial

"Exercise or conversion of derivative security"

exercise price or tax liability financial

"Payment of exercise price or tax liability by delivering or withholding securities"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did GILD’s Chief Medical Officer report on September 10, 2026?

Dietmar Berger reported RSUs vesting into 533 shares of Gilead common stock, with 263 shares delivered or withheld to cover exercise price or tax liability, resulting in 270 net shares acquired as common stock.

How many GILD restricted stock units vested for the Chief Medical Officer?

533 restricted stock units vested, each representing the right to receive one share of Gilead Sciences, Inc.’s common stock, consistent with the RSU award terms.

At what price were GILD shares withheld for tax or exercise obligations?

For the 263 GILD shares delivered or withheld to cover exercise price or tax liability, the reported value was $144.81 per share.

What is the vesting schedule of the GILD restricted stock units in this Form 4?

The RSUs have a 4-year vesting schedule: 25% vest on the first anniversary of the grant date, and the remaining balance vests 6.25% quarterly thereafter until fully vested.

Were the GILD insider transactions made under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported for these transactions by Gilead’s Chief Medical Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 06:30 PM Accepted by SEC EDGAR 09/11/2026 - 06:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berger Dietmar

(Last) (First) (Middle)

333 LAKESIDE DR.

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2026		M		533	A	(1)	19,785	D
Common Stock	09/10/2026		F		263	D	$144.81	19,522	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	09/10/2026		M			533	(2)	(2)	Common Stock	533	(1)	46,395	D

Explanation of Responses:

1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

2. The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

Remarks:

	/s/ Amy Kim by Power of Attorney for Dietmar Berger	09/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)